X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (381) 381
drug combinations (288) 288
albuterol - analogs & derivatives (276) 276
fluticasone-salmeterol drug combination (270) 270
female (268) 268
male (267) 267
index medicus (250) 250
middle aged (223) 223
asthma - drug therapy (200) 200
androstadienes - therapeutic use (181) 181
albuterol - therapeutic use (178) 178
administration, inhalation (176) 176
respiratory system (175) 175
aged (169) 169
salmeterol (169) 169
adult (166) 166
treatment outcome (162) 162
asthma (160) 160
fluticasone (156) 156
pulmonary disease, chronic obstructive - drug therapy (150) 150
androstadienes - administration & dosage (143) 143
albuterol - administration & dosage (137) 137
bronchodilator agents - administration & dosage (129) 129
bronchodilator agents - therapeutic use (126) 126
double-blind method (105) 105
fluticasone propionate (97) 97
adolescent (85) 85
copd (78) 78
obstructive pulmonary-disease (71) 71
drug therapy, combination (70) 70
fluticasone-salmeterol drug combination - administration & dosage (68) 68
pharmacology & pharmacy (67) 67
drug therapy (64) 64
pulmonary disease, chronic obstructive - physiopathology (64) 64
lung diseases, obstructive (63) 63
asthma - physiopathology (62) 62
inhaled corticosteroids (62) 62
chronic obstructive pulmonary disease (61) 61
glucocorticoids - therapeutic use (60) 60
allergy (59) 59
bronchodilator agents - adverse effects (59) 59
corticosteroids (59) 59
androstadienes - adverse effects (57) 57
child (57) 57
exacerbations (56) 56
forced expiratory volume (56) 56
young adult (56) 56
time factors (55) 55
albuterol - adverse effects (53) 53
anti-asthmatic agents - therapeutic use (53) 53
salmeterol xinafoate (52) 52
glucocorticoids - administration & dosage (51) 51
pulmonary/respiratory (51) 51
formoterol fumarate (50) 50
research (50) 50
fluticasone-salmeterol drug combination - therapeutic use (49) 49
formoterol (48) 48
adrenal cortex hormones - administration & dosage (47) 47
severity of illness index (47) 47
pulmonary and respiratory medicine (46) 46
respiratory function tests (46) 46
adrenergic beta-2 receptor agonists - administration & dosage (45) 45
ethanolamines - administration & dosage (45) 45
aged, 80 and over (44) 44
anti-asthmatic agents - administration & dosage (44) 44
nebulizers and vaporizers (44) 44
dosage and administration (42) 42
care and treatment (41) 41
forced expiratory volume - drug effects (41) 41
respiratory tract diseases (41) 41
double-blind (40) 40
lung - physiopathology (40) 40
cross-over studies (39) 39
disease progression (39) 39
ethanolamines - therapeutic use (39) 39
lung - drug effects (39) 39
retrospective studies (39) 39
quality of life (38) 38
diseases of the respiratory system (37) 37
metered dose inhalers (37) 37
propionate (37) 37
budesonide (36) 36
combination (36) 36
mortality (36) 36
budesonide - administration & dosage (35) 35
fluticasone-salmeterol drug combination - adverse effects (35) 35
adrenal cortex hormones - therapeutic use (34) 34
albuterol - economics (34) 34
androstadienes - economics (34) 34
efficacy (33) 33
immunology (33) 33
pulmonary disease, chronic obstructive - diagnosis (33) 33
salmeterol/fluticasone propionate (33) 33
abridged index medicus (32) 32
androstadienes - pharmacology (32) 32
budesonide - therapeutic use (32) 32
tiotropium (32) 32
albuterol - pharmacology (31) 31
steroids (31) 31
cardiac & cardiovascular systems (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (383) 383
Chinese (6) 6
French (6) 6
Japanese (6) 6
Dutch (1) 1
German (1) 1
Portuguese (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 23, pp. 2222 - 2234
Journal Article
Respiratory Medicine, ISSN 0954-6111, 08/2017, Volume 129, pp. 199 - 206
Asthma has a substantial impact on quality of life and health care resources. The identification of a more cost-effective, yet equally efficacious, treatment... 
Fixed-dose combination inhalers | Formoterol | GINA | Cost-effectiveness | Real-life | Asthma | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | EFFICACY | OPEN-LABEL | BUDESONIDE/FORMOTEROL | SALMETEROL | ASTHMA CONTROL | THERAPY | RESPIRATORY SYSTEM | DISEASE | INSIGHTS | Androstadienes - economics | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Ethanolamines - administration & dosage | Asthma - economics | Adult | Female | Cost-Benefit Analysis - economics | Anti-Asthmatic Agents - economics | Treatment Outcome | Ethanolamines - economics | Patient Acceptance of Health Care - statistics & numerical data | Asthma - drug therapy | Fluticasone-Salmeterol Drug Combination - administration & dosage | Drug Therapy, Combination - methods | Androstadienes - administration & dosage | Fluticasone-Salmeterol Drug Combination - economics | Quality of Life | Ethanolamines - therapeutic use | Aged | Androstadienes - therapeutic use | United Kingdom - epidemiology | Drug Combinations | Cohort Studies | Evaluation | Analysis | Pharmacy | Salmeterol | Drugstores | Dosage and administration | Research institutes | Drug therapy, Combination | Steroids | Medical care, Cost of | Health care | Therapy | Costs | Health services | Propionic acid | Fluticasone | Patients | Data bases | Impact analysis | Quality of life | Confidence intervals | Studies | Databases | Chronic obstructive pulmonary disease | Cost analysis | Drug therapy | Drug dosages | Cost engineering
Journal Article
BMC pulmonary medicine, ISSN 1471-2466, 12/2017, Volume 17, Issue 1, pp. 179 - 10
Background: Equitable access to affordable medicines and diagnostic tests is an integral component of optimal clinical care of patients with asthma and chronic... 
Medicines | Diagnostic tests | Access | Uganda | Sub Saharan Africa | Asthma | COPD | MIDDLE-INCOME COUNTRIES | OBSTRUCTIVE PULMONARY-DISEASE | AVAILABILITY | RESPIRATORY SYSTEM | CARE | Drug Costs | Spirometry | Muscarinic Antagonists - economics | Anti-Asthmatic Agents - therapeutic use | Humans | Anti-Asthmatic Agents - supply & distribution | Fluticasone-Salmeterol Drug Combination - therapeutic use | Muscarinic Antagonists - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Adrenal Cortex Hormones - economics | Albuterol - supply & distribution | Budesonide, Formoterol Fumarate Drug Combination - economics | Health Services Accessibility | Diagnostic Techniques, Respiratory System - statistics & numerical data | Adrenergic beta-Agonists - therapeutic use | Albuterol - economics | Leukotriene Antagonists - therapeutic use | Asthma - diagnosis | Pulmonary Disease, Chronic Obstructive - diagnosis | Adrenal Cortex Hormones - supply & distribution | Administration, Inhalation | Budesonide, Formoterol Fumarate Drug Combination - supply & distribution | Adrenergic beta-Agonists - economics | Asthma - drug therapy | Leukotriene Antagonists - economics | Adrenergic beta-Agonists - supply & distribution | Budesonide, Formoterol Fumarate Drug Combination - therapeutic use | Fluticasone-Salmeterol Drug Combination - supply & distribution | Fluticasone-Salmeterol Drug Combination - economics | Muscarinic Antagonists - supply & distribution | Albuterol - therapeutic use | Leukotriene Antagonists - supply & distribution | Respiratory Function Tests | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Care and treatment | Pharmacy | Economic aspects | Drugstores | Medical tests | Respiratory agents | Diagnosis
Journal Article
International journal of chronic obstructive pulmonary disease, ISSN 1178-2005, 2016, Volume 11, Issue 1, pp. 2749 - 2755
Aim: The objective of this study was to evaluate the different outcomes associated with the use of budesonide/formoterol compared to fluticasone/salmeterol in fixed combinations in patients with COPD... 
Exacerbations | Long-acting β2-agonist | Fluticasone/salmeterol | Inhaled corticosteroids | Budesonide/formoterol | COPD | OBSTRUCTIVE PULMONARY-DISEASE | COSTS | RESPIRATORY SYSTEM | exacerbations | long-acting beta 2-agonist | OUTCOMES | fluticasone/salmeterol | budesonide/formoterol | inhaled corticosteroids | Bronchodilator Agents - therapeutic use | Drug Costs | Glucocorticoids - therapeutic use | Humans | Middle Aged | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Budesonide, Formoterol Fumarate Drug Combination - economics | Fluticasone-Salmeterol Drug Combination - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Glucocorticoids - economics | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Retrospective Studies | Bronchodilator Agents - adverse effects | Pulmonary Disease, Chronic Obstructive - economics | Glucocorticoids - adverse effects | Databases, Factual | Bronchodilator Agents - economics | Pulmonary Disease, Chronic Obstructive - diagnosis | Treatment Outcome | Lung - physiopathology | Disease Progression | Propensity Score | Budesonide, Formoterol Fumarate Drug Combination - therapeutic use | Adrenergic beta-2 Receptor Agonists - economics | Budesonide, Formoterol Fumarate Drug Combination - adverse effects | Cost-Benefit Analysis | Lung - drug effects | Fluticasone-Salmeterol Drug Combination - economics | Italy | Administrative Claims, Healthcare | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Medical care, Cost of | long-acting β2-agonist | chronic obstructive pulmonary disease
Journal Article
Journal of internal medicine, ISSN 0954-6820, 2013, Volume 273, Issue 6, pp. 584 - 594
Objectives Combinations of inhaled corticosteroids (ICSs) and long‐acting β2‐agonists (LABAs) are recommended for patients with moderate and severe chronic obstructive pulmonary disease... 
long‐acting β2‐agonists | fluticasone/salmeterol | exacerbations | budesonide/formoterol | inhaled corticosteroids | Exacerbations | Fluticasone/salmeterol | Inhaled corticosteroids | agonists | Budesonide/formoterol | Long-acting β | fluticasone | MANAGEMENT | HEALTHY-SUBJECTS | formoterol | RANDOMIZED CONTROLLED-TRIAL | SALMETEROL/FLUTICASONE | budesonide | PROPIONATE | MEDICINE, GENERAL & INTERNAL | long-acting 2-agonists | salmeterol | BACTERIAL-COLONIZATION | WITHDRAWAL | COPD | Formoterol Fumarate | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Secondary Prevention | Ethanolamines - administration & dosage | Dose-Response Relationship, Drug | Time Factors | Albuterol - administration & dosage | Female | Registries | Retrospective Studies | Drug Therapy, Combination | Administration, Inhalation | Albuterol - analogs & derivatives | Treatment Outcome | Androstadienes - administration & dosage | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Budesonide - administration & dosage | Fluticasone-Salmeterol Drug Combination | Respiratory Function Tests | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Prevention | Medicine, Experimental | Medical research | Lung diseases, Obstructive | Corticosteroids
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 9, pp. 1292 - 1302
Journal Article
Journal Article
International Journal of COPD, ISSN 1176-9106, 04/2015, Volume 10, pp. 775 - 789
... of these patients are not properly diagnosed or managed in the People's Republic of China. The value of combination therapy with inhaled corticosteroids and long-acting beta(2... 
People’s Republic of China | Chronic obstructive pulmonary disease | Fluticasone | Salmeterol | Asthma | fluticasone | DISKUS DEVICE | EFFICACY | SALMETEROL/FLUTICASONE PROPIONATE | INHALED CORTICOSTEROIDS | asthma | PREVALENCE | ECONOMIC BURDEN | OBSTRUCTIVE PULMONARY-DISEASE | RISK-FACTOR | salmeterol | RESPIRATORY SYSTEM | DOUBLE-BLIND | People's Republic of China | 50 MU-G | chronic obstructive pulmonary disease | Bronchodilator Agents - therapeutic use | Drug Costs | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Pulmonary Disease, Chronic Obstructive - ethnology | Asthma - ethnology | Humans | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Asthma - economics | Fluticasone-Salmeterol Drug Combination - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Glucocorticoids - economics | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Bronchodilator Agents - adverse effects | Pulmonary Disease, Chronic Obstructive - economics | Glucocorticoids - adverse effects | Asthma - diagnosis | Bronchodilator Agents - economics | Pulmonary Disease, Chronic Obstructive - diagnosis | Asthma - physiopathology | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | China - epidemiology | Asthma - drug therapy | Fluticasone-Salmeterol Drug Combination - administration & dosage | Asian Continental Ancestry Group | Adrenergic beta-2 Receptor Agonists - economics | Cost-Benefit Analysis | Lung - drug effects | Fluticasone-Salmeterol Drug Combination - economics | Adrenergic beta-2 Receptor Agonists - administration & dosage | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Dosage and administration | Drug therapy, Combination | Drug therapy | Methods
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2011, Volume 105, Issue 10, pp. 1457 - 1466
Journal Article